Elutia Inc (ELUT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.82-2.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELUT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 12.1 | 12.3 | 24.4 | 24.7 | 23.8 | 20.5 | 42.7 |
| Cost of Revenues | 5.1 | 5.7 | 13.7 | 13.7 | 12.2 | 11.2 | 22.1 |
| Gross Profit | 7.0 | 6.6 | 10.7 | 11.1 | 11.6 | 9.3 | 20.6 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 6.8 | 4.2 | 3.8 | 4.4 | 7.7 | 7.8 | 6.0 |
| Operating Income | (26.1) | (26.9) | (35.7) | (30.5) | (35.2) | (28.5) | (13.6) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | 4.8 | 5.8 | 5.1 | 5.3 | 5.6 |
| EBT, Incl. Unusual Items | (22.4) | (15.9) | (54.1) | (41.2) | (36.1) | (30.3) | (21.8) |
| Income Tax Expense | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Earnings from Continuing Operations | (22.4) | (15.9) | (54.1) | (41.2) | (36.2) | (30.3) | — |
| Net Income | |||||||
| Net Income | 51.8 | 53.4 | (53.9) | (37.7) | (32.9) | (24.8) | (21.8) |
| Per Share | |||||||
| Basic EPS | 1.17 | 1.29 | (1.86) | (2.07) | (2.38) | (2.38) | (8.88) |
| Diluted EPS | 1.17 | 0.87 | (1.86) | (2.07) | (2.38) | (2.38) | (8.88) |
| Revenue per Share | 0.27 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 44.2 | 41.4 | 29.1 | 18.2 | 13.8 | 10.4 | 2.9 |
| Diluted Weighted Avg Shares | 44.2 | 45.9 | 29.1 | 18.2 | 13.8 | 10.4 | 2.9 |
| Supplemental | |||||||
| EBITDA | — | (24.1) | (32.2) | (26.8) | (31.5) | (24.8) | (9.7) |
| EBIT | (26.1) | (26.9) | (35.7) | (30.5) | (35.2) | (28.5) | (13.6) |
| Effective Tax Rate | -0.3% | — | — | -0.1% | -0.1% | -0.2% | -0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.